Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant-ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM-2002 study

This publication has 10 references indexed in Scilit:

• Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study
  Journal of Cancer Research and Clinical Oncology, 2023
• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
  Annals of Oncology, 2021
• Frontline therapy for newly diagnosed patients with multiple myeloma
  Blood Research, 2020
• Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
  American Journal of Hematology, 2017
• A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
  Leukemia & Lymphoma, 2016
• Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
  Blood, 2016
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
  The Lancet Oncology, 2014
• Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
  New England Journal of Medicine, 2014
• Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
  Journal of Clinical Oncology, 2010
• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
  New England Journal of Medicine, 2008